Skip to content
lifestyle.humane.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Solid Biosciences Inc.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
June 1, 2026
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 24, 2026
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
May 24, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
May 22, 2026
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
May 22, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
April 7, 2026
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
March 11, 2026
1
2
Next Page
→